The US Food and Drug Administration (FDA) has expanded the approval for lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis) to include adults with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC), who have received androgen receptor pathway inhibitor (ARPI) therapy and are considered appropriate to delay taxane-based chemotherapy. The radioligand therapeutic agent was previously […]
The post FDA Okays Pluvicto for Earlier Use in Prostate Cancer first appeared on News Health.
Author : News Health
Publish date : 2025-03-31 08:47:00
Copyright for syndicated content belongs to the linked Source.